← Back to Search

Thrombectomy Device

Q Revascularization System for Stroke (EvaQ Trial)

N/A

Waitlist Available

Led By Christopher Cognard, PhD, MD

Research Sponsored by MIVI Neuroscience, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up procedure

Awards & highlights

EvaQ Trial Summary

This trial is testing a new medical device to see if it is safe and effective at removing blood clots from the brains of stroke patients.

Eligible Conditions

Stroke
Cerebral Ischemia

EvaQ Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Successful revascularization rate

Symptomatic intracranial haemorrhage rate

Secondary outcome measures

ENT rate

Good functional outcome

ICH

+5 more

EvaQ Trial Design

1Treatment groups

Experimental Treatment

Group I: Q Revascularization SystemExperimental Treatment1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Q Revascularization System

2020

N/A

~130

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

MIVI Neuroscience, Inc.Lead Sponsor

6 Previous Clinical Trials

105 Total Patients Enrolled

5 Trials studying Stroke

85 Patients Enrolled for Stroke

Christopher Cognard, PhD, MDPrincipal InvestigatorHôpital Purpan

Lucas Elijovich, MDPrincipal InvestigatorUniversity of Tennessee Health Sciences Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many venues are engaged in the management of this trial?

"Currently, there are 5 clinical sites actively recruiting participants for this trial. Those locations are in Worcester, Tampa and Buffalo, as well as additional cities. It may be beneficial to choose the closest site so that you can limit travel commitments when taking part in the study."

Answered by AI

What aims has this research endeavor set out to accomplish?

"This clinical trial intends, over the span of its duration, to measure a symptomatic intracranial haemorrhage rate as its primary outcome. Secondary targets for assessment include embolization to a new vascular territory (ENT) during procedure rates, successful revascularization defined as mTICI 2b-3 flow after the first aspiration attempt with the study device rates and finally success in achieving said revascularization following all aspiration attempts from this same study device."

Answered by AI

To what extent is this medical experiment being participated in by individuals?

"Affirmative. The clinical trial portal lists this medical research as currently recruiting volunteers. It was opened on October 27th 2020 and the last update occurred on October 19th 2022, with a goal of 130 participants at 5 distinct sites."

Answered by AI

Are there currently any opportunities to become involved in this clinical trial?

"The information publicly posted on clinicaltrials.gov confirms that this research is in the process of recruiting its cohort. This trial was established October 27th 2020 and last amended 19th October 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke

2020. "A Study to Evaluate the Q Revascularization System for Neurointervention in Acute Ischemic Stroke". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04437862.